Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach

被引:3
|
作者
Dulai, Parambir S. [1 ]
Siegel, Corey A. [2 ]
机构
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
关键词
Crohn's disease; ulcerative colitis; risk; adverse events; inflammatory bowel disease; infections; NONMELANOMA SKIN-CANCER; FACTOR-ALPHA ANTAGONISTS; CROHNS-DISEASE; INCREASED RISK; HEPATITIS-B; CLOSTRIDIUM-DIFFICILE; COMBINATION THERAPY; OPPORTUNISTIC INFECTIONS; MAINTENANCE THERAPY; RECEIVE THIOPURINES;
D O I
10.2174/1389450118666170525114939
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [21] Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study
    Guillo, Lucas
    Uzzan, Mathieu
    Beaugerie, Laurent
    Gornet, Jean-Marc
    Amiot, Aurelien
    Pelletier, Anne-Laure
    Altwegg, Romain
    Laharie, David
    Abitbol, Vered
    Filippi, Jerome
    Goutorbe, Felix
    Nachury, Maria
    Nancey, Stephane
    Viennot, Stephanie
    Reenaers, Catherine
    Amil, Morgane
    Caillo, Ludovic
    Buisson, Anthony
    Collins, Michael
    Picon, Laurence
    Vidon, Mathias
    Benezech, Alban
    Rabaud, Christian
    Baumann, Cedric
    Rousseau, Helene
    Dubourg, Gregory
    Serrero, Melanie
    Peyrin-Biroulet, Laurent
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (04) : 787 - +
  • [22] Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease
    Mahadevan, Uma
    McConnell, Ryan A.
    Chambers, Christina D.
    GASTROENTEROLOGY, 2017, 152 (02) : 451 - +
  • [23] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 767 - 776
  • [24] Genetic profile of patients with early onset inflammatory bowel disease
    Girardelli, Martina
    Basaldella, Federica
    Della Paolera, Sara
    Vuch, Josef
    Tommasini, Alberto
    Martelossi, Stefano
    Crovella, Sergio
    Bianco, Anna Monica
    GENE, 2018, 645 : 18 - 29
  • [25] Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real-world experience
    Yewale, Rohan, V
    Ramakrishna, Balakrishnan S.
    Doraisamy, Babu Vinish
    Basumani, Pandurangan
    Venkataraman, Jayanthi
    Jayaraman, Kayalvizhi
    Murali, Ananthavadivelu
    Premkumar, Karunakaran
    Kumar, Akkim Sathish
    JGH OPEN, 2023, 7 (09): : 599 - 609
  • [26] Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
    Hofmekler, Tatyana
    Bertha, Madeline
    McCracken, Courtney
    Martineau, Benadette
    McKinnon, Elizabeth
    Schoen, Bess T.
    McElhanon, Barbara O.
    Tenjarla, Gayathri
    Kugathasan, Subra
    Sauer, Cary G.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (04) : 580 - 585
  • [27] Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives
    Wellens, Judith
    Vissers, Eva
    Matthys, Christophe
    Vermeire, Severine
    Sabino, Joao
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2023, 16 : 15 - 27
  • [28] Are Nutrition Interventions to Augment Treatment Plans the Most Personalized Approach to Inflammatory Bowel Disease Therapy?
    Barnes, Edward L.
    CROHNS & COLITIS 360, 2020, 2 (03)
  • [29] Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
    Herrera-Gomez, Ruth Gabriela
    Grecea, Miruna
    Gallois, Claire
    Boige, Valerie
    Pautier, Patricia
    Pistilli, Barbara
    Planchard, David
    Malka, David
    Ducreux, Michel
    Mir, Olivier
    CANCERS, 2022, 14 (12)
  • [30] Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
    Satyam, Venkata R.
    Li, Pei-Hsuan
    Reich, Jason
    Qazi, Taha
    Noronha, Ansu
    Wasan, Sharmeel K.
    Farraye, Francis A.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (10) : 2986 - 2991